Cipla Ltd.
BSE: 500087 | NSE: CIPLA
Large Cap | Pharmaceuticals & Drugs
1383.00
6.75 (0.49%) USFDA concludes cGMP inspection at analytical testing facility of Cipla’s arm
Date: 21-02-2025United States Food and Drugs Administration (USFDA) has concluded a current Good Manufacturing Practices (cGMP) inspection at Cipla’s wholly owned subsidiary -- Sitec Labs’ (Sitec) analytical testing facility located in Mahape, Navi Mumbai. The inspection conducted from February 18, 2025 to February 20, 2025.
On conclusion of the inspection, Sitec received two observations in Form 483. The Company will work closely with the USFDA and remains committed to address these observations comprehensively within stipulated time.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.